Please sign in to follow a disease.
Inflammatory myofibroblastic tumor
MONDO:0015798A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults. It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.
Also known as: IMT, inflammatory fibrosarcoma, inflammatory myofibroblastic neoplasm, inflammatory myofibroblastic tumor, inflammatory pseudotumor
1444 clinical trials for this condition and its sub-types, 8 tagged with Inflammatory myofibroblastic tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Inflammatory myofibroblastic tumor
-
Fourth-Generation ALK blocker put to the test against resistant cancers
Disease control Recruiting nowResearchers are testing an experimental drug called SY-12321 in adults with advanced cancers that carry an ALK gene change. These include non-small cell lung cancer, inflammatory myofibroblastic tumor, anaplastic large-cell lymphoma, colorectal cancer, pancreatic cancer, and brea…
Phase 1/2 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: brigatinib trial opens
Disease control Recruiting nowThis study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…
Phase 1/2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC